306 related articles for article (PubMed ID: 28552407)
1. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
[TBL] [Abstract][Full Text] [Related]
2. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
3. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
[TBL] [Abstract][Full Text] [Related]
4. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
6. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
[TBL] [Abstract][Full Text] [Related]
7. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
10. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
12. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
13. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice.
Miao CH; Harmeling BR; Ziegler SF; Yen BC; Torgerson T; Chen L; Yau RJ; Peng B; Thompson AR; Ochs HD; Rawlings DJ
Blood; 2009 Nov; 114(19):4034-44. PubMed ID: 19713458
[TBL] [Abstract][Full Text] [Related]
14. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
Front Immunol; 2020; 11():1293. PubMed ID: 32670285
[TBL] [Abstract][Full Text] [Related]
15. Long-term tolerance to factor VIII is achieved by administration of interleukin-2/interleukin-2 monoclonal antibody complexes and low dosages of factor VIII.
Liu CL; Ye P; Lin J; Djukovic D; Miao CH
J Thromb Haemost; 2014 Jun; 12(6):921-31. PubMed ID: 24684505
[TBL] [Abstract][Full Text] [Related]
16. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
Kootstra NA; Matsumura R; Verma IM
Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
[TBL] [Abstract][Full Text] [Related]
17. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
18. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
Patel SR; Lundgren TS; Spencer HT; Doering CB
Front Immunol; 2020; 11():494. PubMed ID: 32351497
[TBL] [Abstract][Full Text] [Related]
19. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.
Kim YC; Zhang AH; Su Y; Rieder SA; Rossi RJ; Ettinger RA; Pratt KP; Shevach EM; Scott DW
Blood; 2015 Feb; 125(7):1107-15. PubMed ID: 25498909
[TBL] [Abstract][Full Text] [Related]
20. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3+ T regulatory cells.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Chuah M; VandenDriessche T; Miao CH; Hough C; Lillicrap D
Blood; 2009 Jul; 114(3):677-85. PubMed ID: 19458355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]